Mounjaro (Tirzepatide) Drug Intelligence — PatSnap Eureka
Mounjaro (Tirzepatide) Drug Intelligence
Tirzepatide is an approved synthetic peptide dual agonist targeting both GIPR and GLP-1R, first approved May 2022 by Eli Lilly & Co. It spans 18 indications and is expanding commercially across Asia through regional distribution partnerships.
Tirzepatide (Mounjaro): Drug Profile Overview
Tirzepatide is a synthetic peptide originator-developed by Eli Lilly & Co., first approved on May 13, 2022. Active commercial organizations include Eli Lilly & Co., Eli Lilly Japan KK, and Lilly Asia Shanghai Representative Office, reflecting a broad geographic commercial footprint across the US, Japan, and China.
Tirzepatide acts as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Activation of GLP-1R stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. GIPR co-agonism contributes additional insulin secretagogue activity and modulates adipose tissue metabolism and energy balance.
The database records 18 total indications for tirzepatide. Explicitly retrieved approved indications include obesity, obesity hypoventilation syndrome, and obstructive sleep apnea. Patent data additionally references type 2 diabetes, chronic kidney disease, dyslipidemia, NAFLD/NASH, cardiovascular disease, hypertension, metabolic syndrome, and cognitive impairment as research-stage areas.
Eli Lilly & Co. operates through three active geographic entities and has secured two active Asian distribution deals — with Mitsubishi Tanabe Pharma in Japan (2022) and Cipla in India (2025) — demonstrating a consistent co-marketing partnership model for Asian market access rather than wholly-owned infrastructure.
Drugs on the GIP/GLP-1 Dual Receptor Target Axis
The retrieved dataset identifies 2 compounds on the GIPR x GLP-1R target axis: tirzepatide (approved, Eli Lilly & Co.) and ribupatide (development stage, no approval date recorded). Patent data additionally reveals next-generation triple agonist and analog molecules from Hanmi Pharm, Hangzhou Healthytide, and Chengdu Aoda Biotechnology.
Competitor Drugs and Analogs by Development Stage
Tirzepatide is the only approved dual GIP/GLP-1 agonist in the retrieved dataset; ribupatide and analog molecules from Chinese biotechs remain in pre-approval stages.
↗ Click bars to exploreTirzepatide Patent Filings by Theme and Active Status
Core molecule and synthesis themes account for the majority of active patents; combination therapy patents are predominantly PCT-expired, suggesting pipeline reprioritization.
↗ Click bars to exploreTirzepatide Indications: Approved and Research-Stage Applications
The database records 18 total indications for tirzepatide. Three are explicitly named in retrieved records — obesity, obesity hypoventilation syndrome, and obstructive sleep apnea — with additional research-stage areas including type 2 diabetes, chronic kidney disease, NAFLD/NASH, and cardiovascular disease referenced in patent abstracts.
Obesity
Obesity is an explicitly retrieved approved indication for tirzepatide in the database. As a dual GIP/GLP-1 receptor co-agonist, tirzepatide promotes satiety signaling and modulates adipose tissue metabolism and energy balance. This is the anchor commercial indication underpinning the Mounjaro and Zepbound brands.
Metabolic / EndocrineObesity Hypoventilation Syndrome
Obesity hypoventilation syndrome is an explicitly retrieved approved indication for tirzepatide in the database. This respiratory complication of obesity represents a label extension beyond glycemic control, broadening tirzepatide’s addressable patient population. Patent and database records list this among the three named approved indications.
Respiratory / MetabolicObstructive Sleep Apnea
Obstructive sleep apnea is the third explicitly named approved indication retrieved in the tirzepatide database record. It represents a clinically significant comorbidity of obesity treated through the drug’s weight-reduction and metabolic effects. This indication further extends tirzepatide’s commercial and lifecycle management profile.
Respiratory / MetabolicType 2 Diabetes & Cardiometabolic
Patent records US11084861B2, NZ755618A, and WO2019140030A1 (all Eli Lilly) reference type 2 diabetes mellitus as a core indication. CN111320683A (Chengdu Aoda) additionally references cardiovascular disease, hypertension, metabolic syndrome, and cognitive impairment. NAFLD/NASH appears in WO2022187305A1, collectively illustrating tirzepatide’s broad lifecycle management potential across 18 database-recorded indications.
Metabolic / CardiovascularOrganizations in the Tirzepatide IP and Commercial Ecosystem
Eli Lilly & Co. dominates the tirzepatide ecosystem, holding 9 of 20 retrieved patents including all foundational composition-of-matter patents, and operating active commercial entities in the US, Japan, and China. A cluster of Chinese biotechnology firms — including Sinopep Allsino, Chengdu Aoda, and Hangzhou Healthytide — collectively hold 6 active patents focused on synthesis, analogs, and purification.
Top Patent Assignees by Filing Count — Tirzepatide
↗ Click bars to exploreEli Lilly & Co.
Eli Lilly & Co. is the originator and primary commercializing entity for tirzepatide, holding 9 of 20 retrieved patents including foundational composition-of-matter patents NZ755618A (filed 2016) and US11084861B2 (filed 2019), both active. The company operates three active geographic entities (US, Japan, China) and has executed distribution deals with Mitsubishi Tanabe Pharma (Japan, 2022) and Cipla (India, 2025).
United StatesSinopep Allsino Biopharmaceutical
Sinopep Allsino Biopharmaceutical Co Ltd holds 2 active patents on tirzepatide synthesis and manufacturing scale-up: CN112592387A (filed 2020, SPPS method) and CN114736271A (filed 2021, synthesis method). Both patents are active, indicating active preparation for follow-on or generic manufacturing in China. Sinopep Allsino is among the most active Chinese organizations in the tirzepatide IP landscape.
ChinaStrategic Outlook for Tirzepatide in the Dual Incretin Space
Tirzepatide holds first-mover advantage as the only approved dual GIP/GLP-1 co-agonist in the dataset, but faces a narrowing IP exclusivity window and a materializing wave of Chinese generic and analog filings, alongside next-generation triple agonist competition from Hanmi Pharm.
Foundational IP Is Time-Bounded: Exclusivity Cliff Approaching
Eli Lilly’s core GIP/GLP-1 co-agonist composition patents NZ755618A (filed 2016) and US11084861B2 (filed 2019) are both active and central to tirzepatide’s exclusivity. However, the 2016 filing date signals a narrowing window before expiry. IP strategists should model exclusivity cliffs and evaluate whether process patents such as US20220135639A1 and delivery device patent US9402957B2 can extend effective market exclusivity beyond the composition-of-matter expiry.
Chinese Generic Threat Is Materializing in the IP Record
At least five Chinese organizations — Sinopep Allsino, Chengdu Shengnuo, Hangzhou Jiuyuan, Chengdu Aoda, and Hangzhou Healthytide — have filed active patents covering tirzepatide synthesis methods, analogs, or purification processes. BD and regulatory teams should monitor NMPA filings and assess whether these process patents represent freedom-to-operate risks in third-country markets or solely domestic manufacturing preparation ahead of potential generic entry.
Tirzepatide vs Ribupatide: Dual GIP/GLP-1 Agonist Comparison
Click any row to explore further in PatSnap Eureka.
| Dimension | Tirzepatide (Mounjaro) | Ribupatide |
|---|---|---|
| Drug Type | Synthetic peptide | Synthetic peptide |
| Primary Target | GIPR x GLP-1R (dual incretin receptor co-agonist) | GIPR x GLP-1R (same target axis) |
| Mechanism of Action | GIP and GLP-1 receptor co-agonist; stimulates insulin secretion, suppresses glucagon, slows gastric emptying, modulates adipose metabolism | GIP/GLP-1 class mechanism; specific mechanism details not provided in retrieved data |
| Global Status | Approved | Not yet approved (N/A in retrieved data) |
| First Approved | 2022-05-13 | No approval date recorded |
| Key Indications | Obesity; Obesity Hypoventilation Syndrome; Obstructive Sleep Apnea; T2DM (patent-referenced); 18 total database indications | Not specified in retrieved data |
| Originator | Eli Lilly & Co. | Not specified in retrieved data |
| Active Organizations | Eli Lilly & Co.; Eli Lilly Japan KK; Lilly Asia Shanghai Representative Office | Not specified in retrieved data |
Frequently Asked Questions: Mounjaro (Tirzepatide)
Tirzepatide is an approved synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Activation of GLP-1R stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. GIPR co-agonism contributes additional insulin secretagogue activity and modulates adipose tissue metabolism and energy balance, producing effects on glycemic control and body weight reduction.
The database records 18 total indications for tirzepatide. Three are explicitly named in retrieved records: obesity, obesity hypoventilation syndrome, and obstructive sleep apnea. Patent data additionally references type 2 diabetes mellitus, chronic kidney disease, dyslipidemia, NAFLD/NASH, cardiovascular disease, hypertension, metabolic syndrome, and cognitive impairment as research-stage areas.
Eli Lilly & Co. is the primary originator and commercializing entity, with active commercial operations through Eli Lilly Japan KK and Lilly Asia Shanghai Representative Office. The database also lists Lexaria Bioscience Corp. as an originator, though this designation may reflect a formulation or delivery technology claim. Regional commercialization is pursued through distribution partners: Mitsubishi Tanabe Pharma in Japan (deal signed July 2022) and Cipla in India (deal signed October 2025).
The retrieved dataset identifies 2 compounds on the same GIPR x GLP-1R target axis: tirzepatide (approved) and ribupatide (pre-approval, no approval date recorded). The patent record also reveals next-generation competition from Hanmi Pharm Co Ltd (triple agonist EP4043026A1 combining glucagon derivative with GIP/GLP-1 dual agonist) and analog molecules from Chengdu Aoda Biotechnology and Hangzhou Healthytide Biotechnology.
Two active deals are recorded. First, Eli Lilly Japan KK signed a distribution/co-promotion agreement with Mitsubishi Tanabe Pharma for the Japanese market in July 2022, shortly after initial approval. Second, Cipla agreed to market tirzepatide under a second brand name in India in October 2025. Both deals have undisclosed financial values and reflect Lilly’s strategy of leveraging established regional partners for Asian market access.
A total of 20 patents were retrieved. 12 are active, 3 are inactive, 5 are PCT-designated stage expired, and 1 is pending. Eli Lilly & Co. holds 9 patents including the foundational composition-of-matter patents NZ755618A (filed 2016, active) and US11084861B2 (filed 2019, active). Chinese organizations including Sinopep Allsino (2 active), Chengdu Aoda (1 active), and Hangzhou Healthytide (1 active) hold synthesis and analog patents, indicating preparation for potential generic or follow-on manufacturing.
Data and insights on this page are based on a limited patent, clinical, and biopharma intelligence dataset and are for reference only. Figures may not represent the complete drug development landscape.